BZYQT regulated Th2 cytokines in BALF of asthmatic murine model sensitized by OVA.

<p>The concentrations of IL-4 (A), IL-5 (B), and IL-13 (C) were determined by ELISA. Data were presented in mean ± standard deviation. * p < 0.05 compared with the OVA group.</p

HPLC data of Bu-Zhong-Yi-Qi-Tang (BZYQT) (Upper: BZYQT; Lower: standard sample).

<p>The peaks indicate the existence of glycyrrhizin, AHB, Ferulic acid, and MPB in both panels, which proves the authenticity of BZYQT.</p

BZYQT significantly attenuated IgE levels in BALF of OVA-sensitized mice.

<p>These data were measured by ELISA, and presented in mean ± standard deviation. ** p < 0.01 compared with the OVA group.</p

Histopathologic examination of sections of lung and trachea tissues with H&E stain.

<p>Specimens were derived from the control (low power view, A; high power view, B), OVA (low power view, C; high power view, D), LD (low power view, E; high power view, F), and HD (low power view, G; high power view, H) groups, respectively. Notably, eosinophil infiltration over the perivascular and peribronchiolar areas were enhanced in OVA group, and then attenuated in both BZYQT groups significantly.</p

Composition of Bu-Zhong-Yi-Qi-Tang (every 7.56g of water extract are derived from 27g of raw herb).

<p>Composition of Bu-Zhong-Yi-Qi-Tang (every 7.56g of water extract are derived from 27g of raw herb).</p

Effect of oral administration of BZYQT on airway hyperresponsiveness (AHR).

<p>After last OVA challenge, mice were exposed to a series of incremental dosages of methacholine (6.25, 12.5, 25, 50 mg/ml). The Penh values were then recorded, indicating AHR of mice under each dosage of methacholine stimulation. Control group (●, n = 10), OVA group (○, n = 4), Low dose (0.5 g/Kg) BZYQT group (△, n = 8), High dose (1 g/Kg) BZYQT group (▼, n = 8). Data were presented in mean ± standard deviation. ** p< 0.01 compared with the OVA group.</p

The concentration of eosinophil chemoattractant eotaxin (B) and the percentage of eosinophil cell count (A) in BALF were significantly down-regulated in the BZYQT groups.

<p>Data were presented in mean ± standard deviation. * p < 0.05 compared with the OVA group.</p

Table2_The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.XLSX

Esophageal cancer (EC) remains a leading cause of death worldwide and in Taiwan. The prognosis of advanced-stage EC is notably poor, and the treatment options are limited. Chinese herbal medicine (CHM) has been widely used as a complementary treatment for cancer, yet the long-term effect of CHM in stage IV EC remains unclear.The multi-institutional cohort obtained from the Chang Gung research database (CGRD) was used to study the long-term outcome of CHM use among incident stage IV EC patients from 1 January 2002, to 31 December 2018. All patients were followed up to 5 years or the occurrence of death. The overall survival (OS) and disease-specific survival rates were conducted using Kaplan-Meier estimation. Overlap weighing and landmark analysis were used to eliminate confounding and immortal time biases. Furthermore, we demonstrated the core CHMs for stage IV EC by using the Chinese herbal medicine network (CMN) analysis on prescriptions.Nine hundred eighty-five stage IV EC patients were analyzed, including 74 CHM users and 911 non-CHM users. We found the use of CHM was associated with a higher 5-year overall survival rate than CHM nonusers (the cumulative probability: 19.52% versus 6.04%, log-rank test: p The use of CHM seems safe and possibly beneficial among stage IV EC patients with a higher 5-year OS. Further clinical trials on CHM were guaranteed to explore the role of CHM in managing stage IV EC patients.</p

Table1_The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.DOCX

Esophageal cancer (EC) remains a leading cause of death worldwide and in Taiwan. The prognosis of advanced-stage EC is notably poor, and the treatment options are limited. Chinese herbal medicine (CHM) has been widely used as a complementary treatment for cancer, yet the long-term effect of CHM in stage IV EC remains unclear.The multi-institutional cohort obtained from the Chang Gung research database (CGRD) was used to study the long-term outcome of CHM use among incident stage IV EC patients from 1 January 2002, to 31 December 2018. All patients were followed up to 5 years or the occurrence of death. The overall survival (OS) and disease-specific survival rates were conducted using Kaplan-Meier estimation. Overlap weighing and landmark analysis were used to eliminate confounding and immortal time biases. Furthermore, we demonstrated the core CHMs for stage IV EC by using the Chinese herbal medicine network (CMN) analysis on prescriptions.Nine hundred eighty-five stage IV EC patients were analyzed, including 74 CHM users and 911 non-CHM users. We found the use of CHM was associated with a higher 5-year overall survival rate than CHM nonusers (the cumulative probability: 19.52% versus 6.04%, log-rank test: p The use of CHM seems safe and possibly beneficial among stage IV EC patients with a higher 5-year OS. Further clinical trials on CHM were guaranteed to explore the role of CHM in managing stage IV EC patients.</p

Table4_The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.XLSX

Esophageal cancer (EC) remains a leading cause of death worldwide and in Taiwan. The prognosis of advanced-stage EC is notably poor, and the treatment options are limited. Chinese herbal medicine (CHM) has been widely used as a complementary treatment for cancer, yet the long-term effect of CHM in stage IV EC remains unclear.The multi-institutional cohort obtained from the Chang Gung research database (CGRD) was used to study the long-term outcome of CHM use among incident stage IV EC patients from 1 January 2002, to 31 December 2018. All patients were followed up to 5 years or the occurrence of death. The overall survival (OS) and disease-specific survival rates were conducted using Kaplan-Meier estimation. Overlap weighing and landmark analysis were used to eliminate confounding and immortal time biases. Furthermore, we demonstrated the core CHMs for stage IV EC by using the Chinese herbal medicine network (CMN) analysis on prescriptions.Nine hundred eighty-five stage IV EC patients were analyzed, including 74 CHM users and 911 non-CHM users. We found the use of CHM was associated with a higher 5-year overall survival rate than CHM nonusers (the cumulative probability: 19.52% versus 6.04%, log-rank test: p The use of CHM seems safe and possibly beneficial among stage IV EC patients with a higher 5-year OS. Further clinical trials on CHM were guaranteed to explore the role of CHM in managing stage IV EC patients.</p